

**Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin)
Recombinant Antibody
Catalog # APR10424****Specification**

Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) - Product Information

Application	FC, Kinetics, Animal Model
Primary Accession	O95436
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) - Additional Information**Target/Specificity**

NaPi2b / SLC34A2

Endotoxin

< 0.001EU/ µg,determined by LAL method.

Conjugation

MMAE

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) - Protein Information**Name** SLC34A2**Function**

Involved in actively transporting phosphate into cells via Na(+) cotransport.

Cellular Location

Apical cell membrane {ECO:0000250|UniProtKB:Q9DBP0}; Multi-pass membrane protein.

Note=Localized at the brush border membranes of enterocytes.

{ECO:0000250|UniProtKB:Q9DBP0}

Tissue Location


Highly expressed in lung. Also detected in pancreas, kidney, small intestine, ovary, testis, prostate and mammary gland. In lung, it is found in alveolar type II cells but not in bronchiolar epithelium.

Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) - Images



Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-NaPi2b / SLC34A2 Reference Antibody (lifastuzumab vedotin) is more than 95%, determined by SEC-HPLC.